Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels

AIMS: Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments, that is, direct activators of the myosin molecule and Ca(2+) sensitizers for patients with advanced HFrEF. Omecamtiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ráduly, Arnold Péter, Tóth, Attila, Sárkány, Fruzsina, Horváth, Balázs, Szentandrássy, Norbert, Nánási, Péter P., Csanádi, Zoltán, Édes, István, Papp, Zoltán, Borbély, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053277/
https://www.ncbi.nlm.nih.gov/pubmed/36722665
http://dx.doi.org/10.1002/ehf2.14300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053277/
https://www.ncbi.nlm.nih.gov/pubmed/36722665
http://dx.doi.org/10.1002/ehf2.14300

Ejemplares similares